Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Sonoma Pharmaceuticals Inc. Stock

Price
Target price
-

-

-
-
-
-

-

 
Buy 0 Sell 0
Buy 0
Sell 0
WKN: A2PMPH / Symbol: SNOA / Name: Sonoma Pharmaceuticals / Stock / Micro Cap /
Your prediction
Pros and Cons of Sonoma Pharmaceuticals Inc. in the next few years
Wizard

Sonoma Pharmaceuticals Inc. Stock

Our community identified positive and negative aspects for Sonoma Pharmaceuticals Inc. stock for the coming years. 0 users see the criterium "Unique positioning" as a plus for the Sonoma Pharmaceuticals Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
What does Sonoma Pharmaceuticals do?

Pros and Cons of Sonoma Pharmaceuticals Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Sonoma Pharmaceuticals (SNOA) reflects a complex financial picture characterized by several challenges and opportunities. The data reveals a company grappling with substantial operational losses and short-term liquidity issues. However, there are signs of potential that could be harnessed for future growth, especially with revenue dynamics showing some level of improvement. Diving deeper into the financials offers a clearer perspective on the strengths and weaknesses that define Sonoma Pharmaceuticals.

Pros of Sonoma Pharmaceuticals' Financials

Revenue Generation: Sonoma Pharmaceuticals reported total revenue of approximately $12.74 million for the year ending March 2024. This reflects ongoing business operations and a continuous demand for its products, suggesting that the company has a market presence worth capitalizing on.

Show more

Comments

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock.
Ratings data for SNOA provided by MarketBeat
Show more

LADENBURG THALM/SH SH 
0
Report Share
05.09.23 Buy -84.21%
Show more
Not a member yet? Sign up for free!